AIM OF THE REVIEW: The translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and its implementation in daily clinical practice. METHOD: Literature review. RESULTS: A mechanism based approach may be helpful to personalize medicine for the individual patient to which pharmacogenetics may contribute significantly. The lack of consistency in what we accept in bioequivalence and in pharmacogenetics of drug metabolising enzymes is discussed and illustrated with the example of nortriptyline. The impact of pharmacogenetics on examples like tramadol, clopidogrel, coumarins and abacavir is described. Also the present status of the polymorphisms of 5-HT2A and C receptors in antipsychotic-induced weight gain is presented as a pharmacodynamic example with until now a greater distance to clinical implementation. CONCLUSION: The contribution of pharmacogenetics to tailor-made pharmacotherapy, which especially might be of value for patients deviating from the average, has not yet reached the position it seems to deserve.
AIM OF THE REVIEW: The translation of evidence based medicine to a specific patient presents a considerable challenge. We present by means of the examples nortriptyline, tramadol, clopidogrel, coumarins, abacavir and antipsychotics the discrepancy between available pharmacogenetic information and its implementation in daily clinical practice. METHOD: Literature review. RESULTS: A mechanism based approach may be helpful to personalize medicine for the individual patient to which pharmacogenetics may contribute significantly. The lack of consistency in what we accept in bioequivalence and in pharmacogenetics of drug metabolising enzymes is discussed and illustrated with the example of nortriptyline. The impact of pharmacogenetics on examples like tramadol, clopidogrel, coumarins and abacavir is described. Also the present status of the polymorphisms of 5-HT2A and C receptors in antipsychotic-induced weight gain is presented as a pharmacodynamic example with until now a greater distance to clinical implementation. CONCLUSION: The contribution of pharmacogenetics to tailor-made pharmacotherapy, which especially might be of value for patients deviating from the average, has not yet reached the position it seems to deserve.
Authors: J A Lieberman; R B Mailman; G Duncan; L Sikich; M Chakos; D E Nichols; J E Kraus Journal: Biol Psychiatry Date: 1998-12-01 Impact factor: 13.382
Authors: R Kerb; A S Aynacioglu; J Brockmöller; R Schlagenhaufer; S Bauer; T Szekeres; A Hamwi; M Fritzer-Szekeres; C Baumgartner; H Z Ongen; P Güzelbey; I Roots; U Brinkmann Journal: Pharmacogenomics J Date: 2001 Impact factor: 3.550
Authors: Hans Mulder; Barbara Franke; Annemarie Aart van der-Beek van der; Johan Arends; Frederik W Wilmink; Hans Scheffer; Antoine C G Egberts Journal: J Clin Psychopharmacol Date: 2007-08 Impact factor: 3.153
Authors: M Cases; L I Furlong; J Albanell; R B Altman; R Bellazzi; S Boyer; A Brand; A J Brookes; S Brunak; T W Clark; J Gea; P Ghazal; N Graf; R Guigó; T E Klein; N López-Bigas; V Maojo; B Mons; M Musen; J L Oliveira; A Rowe; P Ruch; A Shabo; E H Shortliffe; A Valencia; J van der Lei; M A Mayer; F Sanz Journal: J Intern Med Date: 2013-07-15 Impact factor: 8.989
Authors: Amy L Kaufman; Jared Spitz; Michael Jacobs; Matthew Sorrentino; Shennin Yuen; Keith Danahey; Donald Saner; Teri E Klein; Russ B Altman; Mark J Ratain; Peter H O'Donnell Journal: Mayo Clin Proc Date: 2015-06 Impact factor: 7.616
Authors: Muin J Khoury; Steven B Clauser; Andrew N Freedman; Elizabeth M Gillanders; Russ E Glasgow; William M P Klein; Sheri D Schully Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-07-27 Impact factor: 4.254
Authors: Richard Kia; Rowena L C Sison; James Heslop; Neil R Kitteringham; Neil Hanley; John S Mills; B Kevin Park; Chris E P Goldring Journal: Br J Clin Pharmacol Date: 2013-04 Impact factor: 4.335
Authors: H Robert Superko; Robert Roberts; Arthur Agatston; Stephen Frohwein; Jason S Reingold; Thomas J White; John J Sninsky; Basil Margolis; Kathryn M Momary; Brenda C Garrett; Spencer B King Journal: Curr Atheroscler Rep Date: 2011-10 Impact factor: 5.113
Authors: Manuel A Franco-Martin; Francisco Sans; Belen García-Berrocal; Cristina Blanco; Carlos Llanes-Alvarez; María Isidoro-García Journal: Clin Psychopharmacol Neurosci Date: 2018-08-31 Impact factor: 2.582